All In MedTech

510(k) device

ARK Levetiracetam II Assay

Ark Diagnostics, Inc. · Levetiracetam Assay (ORI, Class II) · First FDA decision Nov 2, 2009, newest Feb 27, 2024Epilepsy

Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

2

510(k) pathway

Device trials

2

Naming "ARK"

MAUDE reports

1

Brand "ARK", since 2015

PubMed studies

1,104

Mentioning "ARK"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing ARK Levetiracetam II Assay

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 2 of 2 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "ARK", any status and sponsor, newest update first.

Open in Trial Radar
  • Ebers Medical Technology, S.L.Not on our public-company list

    NCT05175885 · 100 participants (planned) · Start Dec 14, 2023 · Primary completion Dec 2027

    Device: Ex vivo normothermic perfusion; Cold preservation · For: Kidney Transplantation

    Sites: Zaragoza, Spain

  • Voyager BiomedicalNot on our public-company list

    NCT05490225 · 100 participants (planned) · Start Apr 23, 2025 · Primary completion Mar 25, 2027

    Device: VenaSure · For: Dialysis; Complications; Vascular Access Complication

    Sites: Dothan, Alabama; Riverside, California; Boston, Massachusetts · 8 sites in all

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "ARK", and for the whole product code for context.

This brand

1 reports: 1 malfunction, 0 injury, 0 death

Whole product code ORI

0 reports: 0 malfunction, 0 injury, 0 death

Newest reports for this brand

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

No recall in FDA's data is linked to these FDA numbers.

Published research

The most relevant PubMed records for "ARK"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.